These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 15291696

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Duloxetine for childhood depression with pain and dissociative symptoms.
    Desarkar P, Das A, Sinha VK.
    Eur Child Adolesc Psychiatry; 2006 Dec; 15(8):496-9. PubMed ID: 16732464
    [Abstract] [Full Text] [Related]

  • 24. Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetine.
    Schneider E, Linden M, Weigmann H, Wagner T, Quail D, Hundemer HP, Hegerl U.
    BMC Psychiatry; 2011 Sep 20; 11():150. PubMed ID: 21933428
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Duloxetine's effects in resting functional magnetic resonance imaging of first-episode, drug-naive major depressive disorder with panic disorder patients.
    Lai CH.
    J Neuropsychiatry Clin Neurosci; 2011 Sep 20; 23(3):E10-1. PubMed ID: 21948903
    [No Abstract] [Full Text] [Related]

  • 28. Duloxetine in treatment of anxiety symptoms associated with depression.
    Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ.
    Depress Anxiety; 2003 Sep 20; 18(2):53-61. PubMed ID: 12964171
    [Abstract] [Full Text] [Related]

  • 29. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.
    Mallinckrodt CH, Raskin J, Wohlreich MM, Watkin JG, Detke MJ.
    BMC Psychiatry; 2004 Sep 08; 4():26. PubMed ID: 15355546
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Dual mechanism of action. Remission of physical symptoms].
    MMW Fortschr Med; 2005 May 17; 147 Spec No 2():87. PubMed ID: 15968881
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data.
    Leombruni P, Miniotti M, Colonna F, Sica C, Castelli L, Bruzzone M, Parisi S, Fusaro E, Sarzi-Puttini P, Atzeni F, Torta RG.
    Clin Exp Rheumatol; 2015 May 17; 33(1 Suppl 88):S82-5. PubMed ID: 25786048
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
    Müller N, Schennach R, Riedel M, Möller HJ.
    Expert Rev Neurother; 2008 Apr 17; 8(4):527-36. PubMed ID: 18416656
    [Abstract] [Full Text] [Related]

  • 38. [Expel the fear of pain. Breaking of chronicity by re-learning].
    Ameri AA.
    MMW Fortschr Med; 2009 Dec 10; 151(51-52):51-3. PubMed ID: 20088327
    [No Abstract] [Full Text] [Related]

  • 39. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.
    Romera I, Pérez V, Menchón JM, Schacht A, Papen R, Neuhauser D, Abbar M, Picard H, Gilaberte I.
    J Affect Disord; 2012 Dec 20; 143(1-3):47-55. PubMed ID: 22858211
    [Abstract] [Full Text] [Related]

  • 40. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study.
    Fava M, Martinez JM, Greist J, Marangell LB, Brown E, Chen L, Wohlreich MM.
    Ann Clin Psychiatry; 2007 Dec 20; 19(3):187-95. PubMed ID: 17729021
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.